Gelonghui, November 6 | Tianjing Biotech (IMAB.US) announced today that Dr. Sean (Xi-Yong) Fu (PhD, MBA) has been officially appointed as the company's CEO (“CEO”), effective November 1, 2024. Dr. Fu has served as interim CEO since July 15, 2024 and will continue to be a member of I-Mab's board of directors.
Fu Wei, Chairman of I-Mab's Board of Directors, said, “Sean's appointment is an important step in further I-Mab's mission to deliver breakthrough treatments to patients around the world. During his time as interim CEO, he quickly demonstrated strategic and effective leadership. “Sean has extensive experience in biopharmaceutical product development, cooperative transactions, organizational leadership, etc., and is also an innovative entrepreneur, making him the best person to lead I-Mab.”
Dr. Fu said, “Over the past few months, I have seen the enthusiasm and dedication of the I-Mab team to advance differentiated cancer immunotherapy combinations. I am honored and very excited to continue leading I-Mab to further refine our strategy while advancing our three clinical programs to important milestones. I look forward to working with I-Mab's outstanding team, board, management, and partners to unlock the full potential of our product portfolio to bring new treatment options to cancer patients.”
Dr. Fu has over 20 years of experience in the life sciences industry and has led asset development at multiple clinical stages. Recently, Dr. Fu was an operating partner for Abio-X, a life sciences business incubation platform. Prior to joining Abio-X, Dr. Fu was the co-founder and CEO of RVAC Medicines, an mRNA platform company. Prior to founding RVAC, he was Vice President and Head of International R&D at Luye Pharmaceuticals Group, managing teams in Boston, Princeton, Germany, Switzerland, and Japan. He also served as CEO of Greenleaf's subsidiary Gene Leap, which focuses on DNA and RNA therapies. Prior to that, Dr. Fu worked at Merck & Co. (Merck & Co.) for 15 years, responsible for R&D, business development, finance and operation management, etc., during which time he participated in managing the finance of late-stage clinical projects, and led the integration of the global R&D network after completing a landmark merger totaling 42 billion US dollars between MSD and Schering-Plough Corporation (Schering-Plough Corporation). Dr. Fu has a PhD in materials science and engineering from The Ohio State University and an MBA from the Wharton School of the University of Pennsylvania.
